Navigation Links
Mayo researchers offer new insight into effectiveness of procedure to stop heavy menstrual bleeding
Date:1/5/2009

>

"We've known for the past five to six years that global endometrial ablation devices are very effective," says Mayo Clinic gynecologic surgeon Abimbola Famuyide, M.B.B.S., one of the study's authors. "But some physicians have observed that up to 30 percent of patients may require additional treatment five years and beyond after undergoing ablation."

Undergoing a hysterectomy or another treatment following ablation to achieve permanent symptom relief can be costly and inconvenient for patients. Mayo researchers note that much of the medical research citing failure rates associated with GEA had relatively small study populations and differing definitions of what constituted failure. To establish more precise, population-derived data measuring how many women do not experience permanent symptom relief following GEA, they studied the medical records of approximately 816 women who underwent ablation from Jan. 1, 1998, through Dec. 31, 2005.

"We found that only 16 percent of our subjects required hysterectomy to treat excessive bleeding five years after ablation. That is nearly half of what has generally been reported in the literature to date," explains Dr. Famuyide.

Mayo researchers hypothesized that the low failure rate they observed might mean that their study patients received counseling about realistic expectations for symptom relief. "For example, patients who are seeking complete cessation of menstrual bleeding after GEA are more likely to undergo hysterectomy later to treat bleeding symptoms of any severity," says Dr. Famuyide.

Mayo Clinic research data also showed that patients under age 45, patients who have undergone tubal ligation (a procedure to prevent pregnancy), and patients who experienced debilitating menstrual pain before undergoing GEA were less likely to experience permanent symptom relief following ablation.

According to the Mayo researchers, identifying risk factors that affect treatment outcomes
'/>"/>

Contact: Amy Tieder
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Burnham researchers illuminate mechanisms that regulate DNA damage control and replication
2. Relocation plan of metastatic cancer cells uncovered by Stanford researchers
3. Researchers at Columbia University Medical Center link blood sugar to normal cognitive aging
4. Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting
5. Nutritious fast-food kids meals are scarce, researchers find
6. UIC researchers hunting drugs for devastating parasitic disease
7. Indiana University researchers revisit male bisexuality
8. Breast cancer risk varies in young women with benign breast disease, Mayo Clinic researchers say
9. Mayo researchers find potential links between breast density and breast cancer risk
10. Mayo Clinic researchers find tamoxifens power comes from endoxifen
11. UBC researchers discover gene mutation that causes eye cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients 13118 1Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients 13118 2Next Generation Hemostatic Dressing Available for Military Emergencies 52198 1Next Generation Hemostatic Dressing Available for Military Emergencies 52198 2Next Generation Hemostatic Dressing Available for Military Emergencies 52198 3BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 1BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 2BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 52194 3